Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Balneum Plus cream is a topical over-the-counter combination cream developed by Almirall containing 3% lauromacrogols (polidocanol) and 5% urea. It is primarily used to treat dry, itchy skin conditions such as atopic dermatitis, eczema, and psoriasis. Lauromacrogols act as a local anesthetic and antipruritic agent by inhibiting voltage-gated sodium channels (such as Nav1.7 and Nav1.3) to relieve itching, while urea acts as a humectant and keratolytic agent to hydrate the stratum corneum and restore the skin's natural barrier. The formulation was also investigated in a Phase 4 clinical trial (the 'DON'T ITCH' trial) sponsored by Portsmouth Hospitals NHS Trust for the treatment of chronic kidney disease-associated pruritus (uraemic pruritus) in adult haemodialysis patients, though it did not show a significant difference in itch scores compared to the emollient control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lauromacrogols + urea (Almirall).